Undisclosed EP300 degrader / Hanmi - LARVOL DELTA

Hanmi Pharmaceutical unveils EP300 degrader targeting cancer cells (Chosun Biz) - "Hanmi Pharmaceutical plans to begin a GLP toxicology study, a nonclinical toxicity test, for this substance in the first quarter of next year....Hanmi Pharmaceutical also plans to conduct toxicity tests for this substance in the first quarter of next year and begin a phase 1 clinical trial in the United States in the second half of next year or early the following year."

New P1 trial • Preclinical • Small Cell Lung Cancer